関連する実験動画
Updated: Feb 20, 2026

07:04
Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
Published on: May 2, 2025
1.2K
プログラムされた死亡-リガンド1抑制とSTING活性化の統合:がん治療のための新しいアプローチ
Hossein Khorramdelazad1, Reyhaneh Arfaei2, Pegah Yaraghi3
1Molecular Medicine Research Center, Research Institute of Basic Medical Sciences, Rafsanjan University of Medical Science, Rafsanjan, Iran; Department of Immunology, School of Medicine, Rafsanjan University of Medical Sciences, Rafsanjan, Iran.
Critical reviews in oncology/hematology
|February 18, 2026
まとめ
免疫チェックポイント阻害剤 (ICI) とSTINGアゴニストとの組み合わせは,がん治療において有望であるが,課題に直面している. 新薬の投与とバイオマーカーは,よりよい患者の結果のためにSTING/ICIの組み合わせ戦略を最適化するために不可欠です.
科学分野:
- 免疫学 免疫学とは
- 腫瘍学 腫瘍学
- 薬理学 薬理学とは
背景:
- 免疫チェックポイント阻害剤 (ICI) はがん治療に革命をもたらしましたが,耐性および変異的な結果が持続しています.
- インターフェロン遺伝子刺激 (STING) 経路は,がんにおける免疫応答の重要な調節体であり,腫瘍の微小環境における複雑な役割を持っています.
- STING活性化の二重の役割を理解することは,がん免疫療法における治療的応用にとって極めて重要です.
研究 の 目的:
- STINGアゴニストとPD-1/PD-L1阻害剤を併用する治療の可能性とリスクを批判的に評価する.
- STING/ICI組み合わせ戦略のメカニズム的,翻訳的,および臨床的証拠を合成する.
- 癌の免疫療法を最適化するための新しい薬剤投与プラットフォームとバイオマーカー主導のアプローチを探求する.
主な方法:
- STINGアゴニストとPD-1/PD-L1阻害剤に関する臨床前試験のレビュー.
- STINGアゴニストの早期臨床試験データの分析.
- 癌の免疫療法のための薬物投与システムとバイオマーカーに関する証拠の合成.
主要な成果:
- 臨床前データは,STING/ICIの組み合わせが抗腫瘍免疫を強化することを示唆しています.
- 初期の臨床試験では安全性と経路の関与が示されていますが,回答は控えめで変動しています.
- 課題には,一次耐性,限られた耐久性,異質な臨床結果が含まれています.
結論:
- STING/PD-1/PD-L1の組み合わせ戦略は治療効果が有望だが,慎重に最適化する必要がある.
- 新興薬剤投与プラットフォームとバイオマーカーベースのアプローチは,有効性と安全性の向上に不可欠です.
- 持続的で個別化されたがん治療のためのSTINGベースの免疫療法を進歩させるためにさらなる研究が必要です.
関連する概念動画
Targeted Cancer Therapies
9.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
9.0K
Combination Therapies and Personalized Medicine
6.2K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.2K
The Intrinsic Apoptotic Pathway
8.8K
Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
8.8K
Tumor Immunotherapy
2.0K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.0K
The Extrinsic Apoptotic Pathway
8.9K
The extrinsic apoptotic pathway is initiated when extracellular death-inducing signals, such as specific cytokines, activate the death receptors expressed on the cell surface. The immune cells involved in this pathway are natural killer cells (NK cells) and cytotoxic T-lymphocytes. NK cells are critical in innate immune response, while cytotoxic T-lymphocytes are associated with adaptive immune response. These cells recognize specific receptors expressed on the altered cells and activate...
8.9K

